12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nuedexta dextromethorphan/quinidine regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA from Avanir for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA)....

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >